ANX Mast Therapeutics, Inc.

SAN DIEGO, April 23 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that an abstract entitled 'Synergistic antiretroviral activity of pyrophosphate analogue ANX-201 paired with nucleoside reverse transcriptase inhibitors in vitro' was accepted for presentation at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. The presentation is scheduled for July 23rd. The conference takes place July 22-25, 2007 in Sydney, Australia. About ANX-201 ANX-201 (thiophosphonoformate) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) that is designed as a component of highly active antiretroviral therapy (HAART) for HIV. ANX-201 has been shown in vitro to re-sensitize nucleoside reverse transcriptase inhibitor (NRTI)-resistant virus. The resistance profile of ANX-201 is unique among RTIs reflecting the distinct mechanism of action of this novel drug. ADVENTRX plans to initiate a Phase 1/2 clinical trial of ANX-201 as a component of multi-drug therapy for the treatment of HIV during 2007. About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com/. Forward Looking Statement ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the validity of research results; the risk that preclinical results are not indicative of the success of subsequent clinical trials and that products will not perform as preclinical data suggests or as otherwise anticipated; unexpected adverse side effects or inadequate therapeutic efficacy of ANX-201 and other uncertainties inherent in the drug development process; the timing and success of clinical trials; difficulties or delays in developing, testing, manufacturing, and obtaining regulatory approval for ANX-201, including receiving necessary regulatory approvals for clinical trials of ANX-201; the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones, including funding the continued development of ANX-201; and other risks and uncertainties more fully described in ADVENTRX's press releases and public filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/. ADVENTRX does not intend to update any forward- looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866; or Media, Amy Martini of WeissComm Partners, +1-212-301-7223 Web site: http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/gh/cnoc/comp/920134.html

Copyright